Piper Sandler Sticks to Its Buy Rating for Allogene Therapeutics (ALLO)
Piper Sandler analyst Biren Amin maintained a Buy rating on Allogene Therapeutics (ALLO – Research Report) today and set a price target ...
Strategic Resource Reallocation and Growth Focus Underpin Buy Rating for Allogene Therapeutics
William Blair analyst Sami Corwin has reiterated their bullish stance on ALLO stock, giving a Buy rating on November 11. Sami Corwin has given ...